Substituted benzazoles and methods of their use as inhibitors of raf kinase

US8299108B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Payman Amiri · Emeryville, US
• Wendy J. Fantl · Emeryville, US
• Barry Haskell Levine · Lafayette, US
• Daniel Poon · Piedmont, US
• Savithri Ramurthy · Walnut Creek, US
• Paul A. Renhowe · Danville, US
• Sharadha Subramanian · San Ramon, US
• Leonard Sung · San Mateo, US

Key dates

• Filing date: Sep 29, 2003
• Grant date: Oct 30, 2012
• Expiry date: Sep 29, 2023

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D453/02
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

New substituted benz-azole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.